SR-1375

N/A

Report date: 2025/05/07 16:57:07
NMEFirst In Class

Base Information

Drug NameSR-1375
Drug Alias NameSR-1375
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeuritis inhibitorsLipoprotein-associated phospholipase A2 inhibitors
TargetsLipoprotein-associated phospholipase A2
Therapy Area/IndicationsDiabetic macular oedemaCommunity Acquired PneumoniaRenal Insufficiency, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSimr (Australia) Biotech Pty Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Simr Biotechnology Co LtdSimr (Australia) Biotech Pty LtdShanghai Saimoluode Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaCommunity Acquired PneumoniaRenal Insufficiency, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A